ClinicalTrials.gg
RecruitingNCT04771728Updated Jun 12, 2025

A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis

A Phase 4 interventional study of Metronidazole vaginal suppositories and Metronidazole vaginal suppositories and Probiotics(Umeta-mimi) in Bacterial Vaginosis, sponsored by Peking University Shenzhen Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Peking University Shenzhen Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2020, registered Sep 2020).
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.

Planned enrollment
6th of 16
140 · median 123
Started
2020
the only one that year
Phase 4
6 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
3 of 16
Peking University Shenzhen Hospital

Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 6th largest by planned enrollment, is the only one that started in 2020, is one of 6 in phase 4, and was the 7th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaginosis, Bacterial with a site in China, or all of them as a file.
02

Study summary

The investigators are trying to determine if oral Probiotics(Umeta-mimi,30 days) with Metronidazole vaginal suppositories (7 days) is better than using Metronidazole vaginal suppositories(7 days) only in preventing the recurrence of bacterial vaginosis

Read the detailed description

Studies have shown that oral Probiotics(Umeta-mimi) can significantly promote the recovery of vaginal flora mainly because intestinal microbiota can migrate and affect vaginal microecology. This project aims to evaluate the efficacy of oral Probiotics(Umeta-mimi,30 days) with Metronidazole vaginal suppositories(7 days) in the treatment of bacterial vaginosis (BV) and to explore the correlation between vaginal flora and fecal flora by detecting the metagenomics of vaginal secretions and intestinal feces at the time of baseline phase,14 days after treatment, the first month after treatment, 5-7 days after third menstruation after treatment and 5-7 days after sixth menstruation after treatment

03

Conditions studied

  • Bacterial Vaginosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 55 years old, with history of sexual activity,
  2. Amsel criterion for diagnosing BV
  3. Sign

Exclusion criteria

Exclusion Criteria:

  1. History of systemic organic diseases or psychiatric diseases
  2. Planning for or during pregnancy, lactation, menstruation
  3. within 5 days of onset of the disease, any antibiotics has been used
  4. Long-term use of or
  5. Anaphylactic constitution or allergic to known ingredients of research drugs
  6. No same fixed partner (RSP) before and after treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Metronidazole vaginal

    Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )

    Drug: Metronidazole vaginal suppositories

  • Experimental
    Metronidazole vagianl and Probiotics(Umeta-mimi)

    Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days)

    Drug: Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)

Interventions

  • DrugMetronidazole vaginal suppositories

    Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )

  • DrugMetronidazole vaginal suppositories and Probiotics(Umeta-mimi)

    Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days)

    Also known as: Metronidazole vaginal suppositories adn Probiotics(Umeta-mimi)

06

What researchers measure

Primary outcomes

  1. Cure rate of BV

    Assessments with different Units of Measure:clinical symptoms such as itching or burning; "fishy" smell; homogeneous thin vaginal discharge;Nugent score; pH\>4.5; clue cell.

    Time frame: 14 days after treatment

Secondary outcomes

  1. Recurrence of BV

    Nugent score

    Time frame: The first month after treatment

  2. Recurrence of BV

    Nugent score

    Time frame: 5-7 days after third menstruation after treatment

  3. Recurrence of BV

    Nugent score

    Time frame: 5-7 days after sixth menstruation after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.

Of 17 phase 4 interventional studies under Vaginosis, Bacterial, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 41. This study's planned 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Feb 25, 2021
StartActual
Feb 1, 2020
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04771728
Lead sponsor
Peking University Shenzhen Hospital
Collaborators
BGI, China
Responsible party
Shangrong Fan (Professor of Dept of Obstetrics and Gynecology, Peking University Shenzhen Hospital) — Principal investigator
First posted
Feb 25, 2021
Start date
Feb 1, 2020
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 12, 2025

Study contacts

Shangrong Fan, M.D.
Contact
fanshangrong@163.com
86-755-83923333 ext. 5505
Yiheng Liang, M.D.
Contact
13510331823@163.com
86-755-83923333 ext. 5505
Ruifang Wu, M.D.
study director · Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion